Venture Report: Halda bringing RIPTACs into clinic with crossover round

A new $126 million crossover round will allow Halda Therapeutics Inc. to take the first program from its RIPTAC platform into clinical testing for prostate cancer, as well as a second program for breast cancer.

The funding, a series B extension that more than doubles Halda’s funds raised to date, builds on a $51 million initial close in 2021, as well as a $25 million series A from two years prior. Canaan Partners’ Tim Shannon co-founded Halda in 2019 with Yale University professor Craig Crews...